[Vismodegib Therapy for Periocular Basal Cell Carcinoma].

Area of Science:

• Ophthalmology
• Dermatology
• Oncology

Background:

• Basal cell carcinoma (BCC) is the most frequent tumor affecting the periorbital region.
• While Mohs' surgery is standard, inoperable cases require alternative treatments.
• Vismodegib presents a targeted oral therapy option for BCC.

Observation:

• A retrospective analysis included 4 patients with periorbital BCC treated with vismodegib.
• The patient cohort had a mean age of 87 years and a mean tumor diameter of 22.0 mm.
• Treatment duration averaged 7.5 months with a median follow-up of 17 months.

Findings:

• Complete clinical remission of periorbital BCC was observed in 75% of patients.
• Tumor growth stabilization was achieved in 25% of cases.
• Muscle spasms were the most frequently reported side effect.

Implications:

• Vismodegib is a viable and effective treatment for periorbital BCC in patients unsuitable for surgery.
• This finding supports the use of vismodegib as a crucial therapeutic alternative.
• Further research into vismodegib's efficacy and safety in periorbital BCC is warranted.